Healthcare provider profile · identity verified

John Franklin Swaim, MD

Allopathic & Osteopathic Physicians|Family Medicine · ROCKVILLE, IN · NPI 1760570774

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show John Franklin Swaim, MD received $49.98 in general payments during 2025 across 2 reported records.

Otsuka America Pharmaceutical, Inc. accounted for 50.9% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lantus by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$49.98

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$25.44	50.9%	1	2025
SANOFI-AVENTIS U.S. LLC	Unresolved — no canonical attribution shown	$24.54	49.1%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$49.98	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
REXULTI Normalized: rexulti	Drug	Otsuka America Pharmaceutical, Inc.	$25.44	1	2025
Source payment records 2025-03-04 · Otsuka America Pharmaceutical, Inc. · $25.44 · Open Payments source
TZIELD Normalized: tzield	Biological	SANOFI-AVENTIS U.S. LLC	$24.54	1	2025
Source payment records 2025-02-06 · SANOFI-AVENTIS U.S. LLC · $24.54 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference	2025	LANTUS open payments reported associated product	CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856	Lantus · 2024 Exact normalized brand match · 1 Part D row	12	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1028	121
Furosemide	Furosemide	934	88
Levothyroxine Sodium	Levothyroxine Sodium	750	83
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	695	96
Sertraline Hcl	Sertraline Hcl	614	48
Gabapentin	Gabapentin	578	80
Pantoprazole Sodium	Pantoprazole Sodium	570	61
Donepezil Hcl	Donepezil Hcl	441	27
Losartan Potassium	Losartan Potassium	436	64
Tamsulosin Hcl	Tamsulosin Hcl	406	58
Omeprazole	Omeprazole	403	58
Amlodipine Besylate	Amlodipine Besylate	396	55
Lisinopril	Lisinopril	386	63
Metoprolol Tartrate	Metoprolol Tartrate	385	39
Metoprolol Succinate	Metoprolol Succinate	373	46
Potassium Chloride	Potassium Chloride	372	47
Tramadol Hcl	Tramadol Hcl	351	56
Famotidine	Famotidine	337	34
Memantine Hcl	Memantine Hcl	305	27
Clopidogrel	Clopidogrel Bisulfate	302	46
Eliquis	Apixaban	301	32
Metformin Hcl	Metformin Hcl	292	53
Risperidone	Risperidone	292	19
Alprazolam	Alprazolam	238	41
Glipizide	Glipizide	226	39
Finasteride	Finasteride	224	42
Carvedilol	Carvedilol	207	31
Xarelto	Rivaroxaban	202	23
Trazodone Hcl	Trazodone Hcl	200	38
Mirtazapine	Mirtazapine	183	16
Methylprednisolone	Methylprednisolone	182	109
Fluoxetine Hcl	Fluoxetine Hcl	178	24
Lorazepam	Lorazepam	172	23
Pioglitazone Hcl	Pioglitazone Hcl	171	32
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	163	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	163	23
Albuterol Sulfate Hfa	Albuterol Sulfate	162	40
Allopurinol	Allopurinol	162	25
Duloxetine Hcl	Duloxetine Hcl	161	24
Simvastatin	Simvastatin	161	28
Prednisone	Prednisone	160	47
Ibuprofen	Ibuprofen	152	41
Atenolol	Atenolol	151	18
Ropinirole Hcl	Ropinirole Hcl	150	17
Cephalexin	Cephalexin	143	85
Tizanidine Hcl	Tizanidine Hcl	140	12
Oxybutynin Chloride	Oxybutynin Chloride	132	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	126	26
Warfarin Sodium	Warfarin Sodium	126	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	121	42
Hydrochlorothiazide	Hydrochlorothiazide	119	22
Jardiance	Empagliflozin	118	18
Alendronate Sodium	Alendronate Sodium	112	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	106	49
Hydralazine Hcl	Hydralazine Hcl	102	12
Meloxicam	Meloxicam	102	30
Pravastatin Sodium	Pravastatin Sodium	101	25
Metformin Hcl Er	Metformin Hcl	100	19
Buspirone Hcl	Buspirone Hcl	97	14
Meclizine Hcl	Meclizine Hcl	96	20
Chlorthalidone	Chlorthalidone	93	suppressed
Clonazepam	Clonazepam	91	14
Olanzapine	Olanzapine	90	suppressed
Levetiracetam	Levetiracetam	87	suppressed
Memantine Hcl Er	Memantine Hcl	87	suppressed
Ezetimibe	Ezetimibe	82	19
Triamcinolone Acetonide	Triamcinolone Acetonide	82	41
Glipizide Er	Glipizide	81	23
Amoxicillin	Amoxicillin	80	56
Carbidopa-Levodopa	Carbidopa/Levodopa	79	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	79	13
Terazosin Hcl	Terazosin Hcl	77	suppressed
Amantadine	Amantadine Hcl	74	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	72	15
Citalopram Hbr	Citalopram Hydrobromide	67	11
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	66	suppressed
Namzaric	Memantine Hcl/Donepezil Hcl	64	suppressed
Theophylline Er	Theophylline Anhydrous	64	11
Lamotrigine	Lamotrigine	63	suppressed
Diazepam	Diazepam	62	13
Zolpidem Tartrate	Zolpidem Tartrate	61	suppressed
Divalproex Sodium	Divalproex Sodium	59	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	59	22
Torsemide	Torsemide	58	suppressed
Galantamine Hbr	Galantamine Hbr	52	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	52	suppressed
Ventolin Hfa	Albuterol Sulfate	52	16
Celecoxib	Celecoxib	50	19
Quetiapine Fumarate	Quetiapine Fumarate	50	11
Amiodarone Hcl	Amiodarone Hcl	49	suppressed
Naproxen	Naproxen	49	19
Fenofibrate	Fenofibrate Nanocrystallized	47	suppressed
Latanoprost	Latanoprost	47	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	46	16
Sucralfate	Sucralfate	46	suppressed
Azithromycin	Azithromycin	45	28
Montelukast Sodium	Montelukast Sodium	43	suppressed
Ozempic	Semaglutide	43	suppressed
Januvia	Sitagliptin Phosphate	42	suppressed
Pregabalin	Pregabalin	42	11
Entresto	Sacubitril/Valsartan	41	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	40	suppressed
Haloperidol	Haloperidol	40	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	39	suppressed
Phenytoin	Phenytoin	38	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	37	11
Ciprofloxacin Hcl	Ciprofloxacin Hcl	37	18
Venlafaxine Hcl Er	Venlafaxine Hcl	37	suppressed
Brilinta	Ticagrelor	36	suppressed
Fesoterodine Fumarate Er	Fesoterodine Fumarate	36	suppressed
Topiramate	Topiramate	36	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	36	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	35	suppressed
Bumetanide	Bumetanide	35	suppressed
Digoxin	Digoxin	35	suppressed
Ondansetron Hcl	Ondansetron Hcl	35	19
Ramipril	Ramipril	35	suppressed
Vraylar	Cariprazine Hcl	35	suppressed
Albuterol Sulfate	Albuterol Sulfate	34	14
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	34	13
Mycophenolate Mofetil	Mycophenolate Mofetil	34	suppressed
Fluticasone Propionate	Fluticasone Propionate	33	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	33	11
Fluconazole	Fluconazole	32	13
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	32	19
Doxycycline Hyclate	Doxycycline Hyclate	31	21
Mounjaro	Tirzepatide	31	suppressed
Nitroglycerin	Nitroglycerin	29	20
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	28	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	28	suppressed
Gentamicin Sulfate	Gentamicin Sulfate	28	23
Phenytoin Sodium Extended	Phenytoin Sodium Extended	28	suppressed
Symbicort	Budesonide/Formoterol Fumarate	28	suppressed
Nifedipine Er	Nifedipine	27	suppressed
Oxcarbazepine	Oxcarbazepine	27	suppressed
Tresiba	Insulin Degludec	27	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	26	13
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	26	17
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	26	suppressed
Spironolactone	Spironolactone	26	12
Ceftriaxone	Ceftriaxone Sodium	24	17
Novolin 70-30	Insulin Nph Hum/Reg Insulin Hm	24	suppressed
Nystatin	Nystatin	24	11
Primidone	Primidone	24	suppressed
Ondansetron Odt	Ondansetron	23	14
Bupropion Xl	Bupropion Hcl	22	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	22	12
Methocarbamol	Methocarbamol	22	suppressed
Loperamide	Loperamide Hcl	21	11
Methenamine Hippurate	Methenamine Hippurate	21	suppressed
Baclofen	Baclofen	20	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	20	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	19	suppressed
Clonidine	Clonidine	19	suppressed
Synthroid	Levothyroxine Sodium	19	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	18	suppressed
Myrbetriq	Mirabegron	18	suppressed
Oxycodone Hcl	Oxycodone Hcl	18	suppressed
Paroxetine Hcl	Paroxetine Hcl	18	suppressed
Breo Ellipta	Fluticasone/Vilanterol	17	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	16	suppressed
Diclofenac Sodium	Diclofenac Sodium	16	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	16	12
Esomeprazole Magnesium	Esomeprazole Magnesium	16	suppressed
Midodrine Hcl	Midodrine Hcl	15	suppressed
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	15	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	14	suppressed
Klor-Con M20	Potassium Chloride	14	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	14	suppressed
Aripiprazole	Aripiprazole	13	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	13	suppressed
Fenofibrate	Fenofibrate	13	suppressed
Lovastatin	Lovastatin	13	suppressed
Oseltamivir Phosphate	Oseltamivir Phosphate	13	13
Sumatriptan Succinate	Sumatriptan Succinate	13	suppressed
Travoprost	Travoprost	13	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Lidocaine Hcl	Lidocaine Hcl	12	12
Nortriptyline Hcl	Nortriptyline Hcl	12	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	11	suppressed
Diltiazem Hcl	Diltiazem Hcl	11	suppressed
Enoxaparin Sodium	Enoxaparin Sodium	11	suppressed
Estradiol	Estradiol	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Invega Sustenna	Paliperidone Palmitate	11	suppressed
Lactulose	Lactulose	11	suppressed
Leukeran	Chlorambucil	11	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed
Triazolam	Triazolam	11	suppressed
Trueplus Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$49.98 · 2 records	Otsuka America Pharmaceutical, Inc.	REXULTI, TZIELD	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with SANOFI-AVENTIS U.S. LLC?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error